Pacgenomics

Pacgenomics was paid $12.86M by Medicaid between Jan 2021 and Dec 2024, across 17 billing codes. Its largest line is 87635, Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe — 24% of everything it billed.

33Billing provider infoPACGENOMICS
AGOURA HILLS, CA 91301

33aNPI1841715471assigned 08/04/2017

33bProvider typeClinical Medical Laboratory

28Total paid$12.86M

24GClaims432,980

24DCodes billed17

24AFirst – last monthJan 2021 – Dec 2024

Compared with peers

Next to other Clinical Medical Laboratory providers in California

Rank by total paid#59 of 561

Median peer was paid$222K

This provider vs. median58×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2021	8,448	$238K
2022	71,982	$2.76M
2023	91,635	$2.27M
2024incomplete	260,915	$7.59M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	24%	94,090	39,702	$3.03M
87632		20%	31,516	18,460	$2.57M
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	20%	38,354	17,681	$2.55M
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	12%	60,983	31,486	$1.59M
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	6.8%	43,559	17,977	$876K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	3.9%	29,893	15,848	$499K
87486		3.9%	28,648	16,179	$499K
87581		3.8%	28,492	16,039	$489K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	2.9%	20,619	9,709	$374K
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	2.4%	52,580	16,489	$303K
87631		<1%	1,783	1,247	$41K
87634		<1%	1,625	1,131	$40K

5 more codes

87428		<1%	86	$5K
86769		<1%	34	$642.72
K1034	Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count	<1%	690	$359.64
86408		<1%	13	$252.78
86328		<1%	15	$180.92

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialOLSAN, KENT (ADMINISTRATOR)